Invesco S&P MidCap 400 QVM Multi-factor ETF
QVMM - ETF AI Analysis
Top Page
Invesco S&P MidCap 400 QVM Multi-factor ETF (QVMM)
QVMM, the Invesco S&P MidCap 400 QVM Multi-factor ETF, is supported by several strong mid-cap holdings with solid financial performance and generally positive outlooks, which together point to a well-built, quality fund. Standout positions like United Therapeutics, Royal Gold, ATI, TechnipFMC, and Woodward contribute positively through robust revenue growth, healthy balance sheets, and bullish technical trends, while names such as XPO and ITT introduce some caution due to high leverage, legal or valuation concerns, and potential short-term technical weakness. The main risk factor is that many top holdings share similar issues around higher valuations and occasional overbought conditions, which could make the fund more sensitive to market pullbacks.
QVMM vs. SPDR S&P 500 ETF (SPY)
- AUM
- 423.67M
- Region
- North America
- Expense Ratio
- 0.15%
- Beta
- 0.84
- Issuer
- Invesco
- Inception Date
- Jun 30, 2021
- Dividend Yield
- 1.25%
- Asset Class
- Equity
- Index Tracked
- S&P MidCap 400 Quality, Value & Momentum Top 90% Multi-factor Index (USD)
QVMM Summary
The Invesco S&P MidCap 400 QVM Multi-factor ETF (QVMM) invests in medium-sized U.S. companies and follows the S&P MidCap 400 Quality, Value & Momentum Index. It focuses on businesses that look financially strong, reasonably priced, and showing positive stock trends. The fund spreads money across many sectors, including industrials, financials, technology, and health care, and holds well-known names like Okta and United Therapeutics. Someone might invest in QVMM to tap into the growth potential of mid-sized companies while diversifying beyond large caps. A key risk is that mid-cap stocks can be more volatile and can go up and down with the overall stock market.
How much will it cost me?
This ETF has an expense ratio of 0.15%, which means you’ll pay about $1.50 per year for every $1,000 you invest. That cost is slightly below average for a specialized, rules-based ETF, because while it uses a multi-factor strategy, it still tracks an index rather than being fully actively managed.
What would affect this ETF?
This U.S. mid-cap ETF could benefit if the economy grows steadily, supporting industrial, technology, and consumer cyclical companies, and if investors favor quality, value, and momentum strategies. On the downside, higher interest rates, economic slowdowns, or sector-specific issues in areas like financials, health care, or real estate could hurt its holdings and weigh on future performance.
QVMM Top 10 Holdings
QVMM is a U.S.-focused mid-cap fund where a handful of industrials, health care, and tech names set the tone. Okta and Entegris have been rising, giving the ETF a lift from the technology side, while United Therapeutics and Tenet Healthcare add steady strength from health care. On the industrial front, Reliance Steel has been climbing, but ATI and nVent Electric have turned more mixed to lagging lately, occasionally acting as a speed bump. Overall, the fund leans into cyclical, domestically driven growth stories rather than global mega-cap tech.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| TechnipFMC | 0.86% | $3.64M | $25.76B | 53.52% | 80Outperform | |
| US Foods Holding | 0.83% | $3.52M | $23.28B | 50.35% | 74Outperform | |
| United Therapeutics | 0.82% | $3.46M | $25.18B | 27.88% | 79Outperform | |
| ATI | 0.80% | $3.39M | $24.87B | 85.77% | 78Outperform | |
| Tenet Healthcare | 0.79% | $3.34M | $22.76B | 45.44% | 74Outperform | |
| XPO | 0.77% | $3.27M | $22.46B | 42.33% | 70Outperform | |
| Entegris | 0.69% | $2.92M | $22.52B | 81.85% | 66Neutral | |
| Royal Gold | 0.68% | $2.86M | $21.72B | 35.58% | 78Outperform | |
| Reliance Steel | 0.69% | $2.91M | $21.77B | 56.27% | 74Outperform | |
| Woodward | 0.64% | $2.71M | $19.48B | 25.28% | 79Outperform |
QVMM Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QVMM, the sentiment is Positive. The current price of 34.67 is above the 20-day moving average (MA) of 34.35, above the 50-day MA of 34.20, and above the 200-day MA of 34.07, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 53.42 is Neutral, neither overbought nor oversold. The STOCH value of 80.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QVMM.
QVMM Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $34.67 | $38.00(9.59% Upside) | $423.67M | 0.15% | 72Outperform | |
| $75.60 | $88.10(16.53% Upside) | $950.99M | 0.38% | 70Neutral | |
| $67.05 | $73.66(9.86% Upside) | $730.22M | 0.25% | 71Outperform | |
| $39.52 | $48.57(22.89% Upside) | $651.75M | 0.04% | 68Neutral | |
| $144.92 | $162.71(12.27% Upside) | $611.74M | 0.35% | 74Outperform | |
| $79.25 | $93.90(18.48% Upside) | $558.86M | 0.18% | 70Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| QVMM | Invesco S&P MidCap 400 QVM Multi-factor ETF | 34.67 | 5.74 | 19.84% | |
| EZM | WisdomTree U.S. MidCap Fund | 75.60 | 12.79 | 20.36% | |
| XMLV | Invesco S&P MidCap Low Volatility ETF | 67.05 | 6.84 | 11.36% | |
| BKMC | BNY Mellon US Mid Cap Core Equity ETF | 39.52 | 5.30 | 15.47% | |
| GRPM | Invesco S&P MidCap 400 GARP ETF | 144.92 | 31.14 | 27.36% | |
| AVMC | Avantis U.S. Mid Cap Equity ETF | 79.25 | 12.41 | 18.56% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
